Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis

Efficacy of Topical Tapinarof Versus Betamethasone in the Treatment of Plaque Psoriasis

To assess the effectiveness of topical tapinarof to topical betamethasone in patients with mild to moderate plaque psoriasis presenting to tertiary care hospital in Islamabad

Inclusion Criteria:

• Age 18 years-65 years
• Clinically diagnosed plaque psoriasis involving body surface area ( BSA) of 2-20% (mild to moderate severity)
• Disease duration of at least 6 months
• Willing and able to provide written informed consent
• Not currently using any other topical and systematic psoriasis therapy, or willing to undergo a washout period (2 weeks for topical therapies)

Exclusion Criteria:

• Severe psoriasis (BSA >20% or requiring systemic therapy)
• Pregnant and lactating mothers
• Known hypersensitivity to Tapinarof or any of its excipients
• Concurrent dermatological conditions that may interfere with assessment e.g fungal infections,atopic dermatitis
• Use of systemic immunosuppressants (methotrexate, cyclosporine, biologics ) or phototherapy within 4 weeks before enrollment
• History of malignancy or current active infection
• Known hypersensitivity to betamethasone or Tapinarof
• Use of powerful topical corticosteroids within two weeks previously